An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology, and Response to Treatment
Summary
This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.
Detailed description
PRIMARY OBJECTIVES: I. To collect germ-line deoxyribonucleic acid (DNA) and nucleic acids from cancer patients to further investigate the association and identify new germ-line mutations that impact cancer predisposition. II. To investigate the role of germ-line mutations in predicting cancer outcome and response to therapy. SECONDARY OBJECTIVES: I. To determine the effect of the identified variants on tumor micro-ribonucleic acid (miRNA), protein and gene expression. II. To study expression of DNA, ribonucleic acid (RNA) or protein in the blood of cancer patients with and without variants of interest to discover correlations between such levels and the presence of cancer and/or response to therapy in these patients. OUTLINE: Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis. After completion of study, patients are followed up for 5 years.
Arms & interventions
- Othercytology specimen collection procedure
Correlative studies
Outcome measures
Primary
Prevalence of germ-line variants
The prevalence of germ-line variants of interest will be compared to the baseline prevalence found using available large human genomic DNA collections. The primary statistical analysis will involve comparisons of genotypes between with (cases) and without (controls) the germ-line mutation. This analysis will include Pearson's chi-square analysis or Fisher's exact test and computation of odds ratios to assess the relationship of the genetic polymorphism and cancer risk.
Time frame: Up to 5 years
Overall genotype frequencies
The overall genotype frequencies among the cases and expected control levels will first be compared with the frequencies expected from Hardy-Weinberg equilibrium by goodness-of-fit chi-square. Odds ratios and 95% confidence intervals will be used to estimate risk associated with the variant genotypes by using both univariate and unconditional multivariate logistic regression models.
Time frame: Up to 5 years
Response to treatment
The impact of inherited variants on response to treatment will be determined.
Time frame: Up to 5 years
Cancer development
The role of inherited variants in clinical and pathological cancer development will be determined.
Time frame: Up to 5 years
Eligibility criteria
Study locations (1)
Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095